Healthcare Providers and Services
Company Overview of Critical Care Diagnostics Inc.
Critical Care Diagnostics, Inc. develops laboratory assays for the cardiovascular diseases. It offers Presage, a laboratory assay employing ST2 for the diagnosis and prognosis of cardiovascular disease. The company was incorporated in 2004 and is based in New York, New York.
802 6th Avenue
New York, NY 10001
Founded in 2004
Key Executives for Critical Care Diagnostics Inc.
President and Member of the Management Board
Senior Vice President of Sales & Business Development
Director of Critical Diagnostics and Member of the Management Board
Compensation as of Fiscal Year 2013.
Critical Care Diagnostics Inc. Key Developments
Critical Diagnostics Elects Richard Dee to its Board of Directors
Oct 29 13
Critical Diagnostics announced the election of Richard Dee to its Board of Directors. Richard is a Board Director and Senior Vice President at Unilab in Manila, Philippines. He oversees Unilab's regional interests in biotechnology and most recently, diagnostics. Richard's career in Unilab spans over two decades and continues to be focused on ethical medicine business development.
Critical Diagnostics Unveils Aspect-LF ST2 Test
Oct 21 13
Critical Diagnostics has unveiled its Aspect-LF ST2 test, a point-of-care version of the company's lab-based Presage ST2 assay. Aspect-LF is a disposable cartridge, based on lateral flow technology that uses finger-stick whole blood for qualitatively measuring ST2. Results take approximately twenty minutes, enabling physicians to receive vital information on a patient's heart failure disease status while still in the doctor's office or clinic - which can
aid greatly in treatment decisions.
Critical Care Diagnostics Inc. Signs Agreement for Presage ST2 Assay with Quest Diagnostics Inc., Berkeley HeartLab, Inc. and Laboratory Corp. of America Holdings
Dec 20 12
Critical Care Diagnostics Inc. and Quest Diagnostics Inc. and its subsidiary Berkeley HeartLab Inc. announced an agreement under which both Quest and Berkeley HeartLab will offer ST2 testing services based on Critical Diagnostics Presage ST2 Assay. Critical Diagnostics has also signed an agreement with Laboratory Corp. of America Holdings to offer testing of the Presage ST2 Assay. Combined, these two diagnostic leaders perform some one-and-a-half million tests per day. The Presage ST2 Assay is FDA cleared for use in assessing the prognosis of patients diagnosed with chronic heart failure. Clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death. For instance, chronic heart failure patients with ST2 levels above the standard cutpoint, have a three times greater risk of 30-day rehospitalization or mortality. Unlike many other cardiac biomarkers, ST2 levels change quickly in response to changes in the patient's condition -thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust care. Furthermore, prognostic information from soluble ST2 is independent of and complimentary to natriuretic peptide markers like BNP and NT-proBNP, and unlike natriuretic peptide markers, is not adversely affected by such confounding factors as age, gender, body mass index and impaired renal failure.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|